about
GDNF is not required for catecholaminergic neuron survival in vivoCharacterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease.The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease.Highly efficient generation of induced neurons from human fibroblasts that survive transplantation into the adult rat brain.Generation of induced neurons via direct conversion in vivo.Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease.Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonismMonosynaptic Tracing using Modified Rabies Virus Reveals Early and Extensive Circuit Integration of Human Embryonic Stem Cell-Derived Neurons.Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's DiseaseSynaptic inputs from stroke-injured brain to grafted human stem cell-derived neurons activated by sensory stimuli.Human foetal brain tissue as quality control when developing stem cells towards cell replacement therapy for neurological diseases.Brain repair and reprogramming: the route to clinical translation.Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain.Plug and Play Brain: Understanding Integration of Transplanted Neurons for Brain Repair.In Vivo Reprogramming of Striatal NG2 Glia into Functional Neurons that Integrate into Local Host Circuitry.IAP-Based Cell Sorting Results in Homogeneous Transplantable Dopaminergic Precursor Cells Derived from Human Pluripotent Stem Cells.Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat.Lineage reprogramming: a shortcut to generating functional neurons from fibroblasts.The future of stem cell therapies for Parkinson disease
P50
Q27312615-0D96B079-DFB2-4437-8E06-B9B51C150F92Q33596638-8ED54ABF-3D46-4FC3-9349-A6BEE5E7706BQ33656315-1A34D393-59F7-4E42-A12D-D9C702B18490Q34162515-5FAD7D1B-0692-415E-8591-0879490CE8C8Q34335374-A8FA5D33-647A-422C-87F9-DB5CFBC7F06AQ34515645-057C2352-DF66-44D6-A902-38ED175C0729Q35028568-55343C6E-EF30-4489-A775-2FAF14D494A0Q35754374-E47DF0DD-76DB-4AC3-99B6-710DF35F3770Q36250893-E238BFBF-5655-4E01-95F0-635225800527Q36258150-8DBD82ED-319E-4C5D-ABFF-0DB1F4A21CD1Q38164497-76E5E92A-7458-4EF0-B0B4-F5169D75A4A0Q38829948-AF7D33FB-37AE-4003-AF43-BA72FC813EC8Q39813486-5C3D25B2-9677-4617-BFCD-F4FA3CAC051CQ40444510-91884ADD-FB7A-4AD0-B9B7-2E5813A3DAFEQ41593150-9BE43DBA-319D-42CE-8E4B-37EFA8E92F1CQ42376393-ED752786-5388-4A34-B75A-EF8DE11F3DDAQ46346503-502CCB89-0146-4550-8B5C-EBE74412775DQ53207363-209A9CD6-9F54-4CD6-8527-0C21553ED8D2Q92453609-82670AD6-AB4C-49A4-9BE5-D02925061A19
P50
description
researcher ORCID ID = 0000-0002-7676-7924
@en
wetenschapper
@nl
name
Shane Grealish
@ast
Shane Grealish
@en
Shane Grealish
@es
Shane Grealish
@nl
type
label
Shane Grealish
@ast
Shane Grealish
@en
Shane Grealish
@es
Shane Grealish
@nl
prefLabel
Shane Grealish
@ast
Shane Grealish
@en
Shane Grealish
@es
Shane Grealish
@nl
P106
P1153
25623075700
P31
P496
0000-0002-7676-7924